
optomap®

MULTIMODALITY UWF IMAGING THAT IMPROVES CLINICAL PRACTICE





















optomap is multimodality imaging technology, able to generate high-resolution 200° ultra-widefield (UWFTM) images to visualize vitreoretinal*, retinal and choriodal layers from pole to periphery.

- optomap is the only single capture consensus-defined UWF image²
- 4 **opto**map images are captured in less than $\frac{1}{2}$ second through an undilated pupil
- 2500+ peer-reviewed publications in 179 diseases demonstrate the value of optomap
- optomap use enhances pathology detection, disease management, and clinic flow^{12,3}
- OptosAdvance™ software streamlines image review and enables images to be overlaid to assess changes overtime

"Optos imaging has revolutionized retina and is indispensable in the management of retinal vascular diseases."

- David M. Brown, MD Retina Consultants of Texas

See how **opto**map will help you manage your patients. For more information call **800-854-3039** or **BDS@optos.com**.





Page 1 of 2 GA-00417/2

CLINICAL SUMMARY

The ONLY single capture multimodality UWF retinal imaging

- **opto**map utility has been evaluated for the use across 179 diseases in 2500+ publications demonstrating equivalence with traditional single and multi-capture fundus photos and OCT for:
 - DR & DME4-10
 - AMD and GA11
 - ROP12
 - Uveitis / Vasculitis¹³
 - Sickle cell¹⁴
- optomap color rg may allow a better evaluation of:
 - Vascular disease^{1,4-10}
 - RPE changes1
 - Pigment dispersion due to laser¹
 - Deep retinal hemorrhages in diabetic retinopathy^{1,4-10}
 - Nevus¹⁵
 - Myopia^{16,17}
 - Ocular oncology^{16,17}
 - Inflammatory disease^{16,17}
 - Inherited retinal disorders 16,17
- optomap color rgb may improve the ability to differentiate1:
 - Optic nerve anatomy
 - Hyaloid reflection
 - PVR subretinal band
 - Peripheral retinal abnormalities (holes, tears, lattice)
 - Superficial retinal hemorrhages
 - Neovascularization
 - Ghost vessels or ischemia
 - Enhanced contrast between the retinopexy
 - Retinoschisis¹⁸
- optomap stereo imaging equivalent for glaucoma assessment¹⁹



- optomap is able to image through cataracts 85% of the time²⁰ and reduces ungradable images in 81%²¹
- optomap af is available in green (532nm) and blue (488nm)*
 - optomap green af finds peripheral changes in 66%²² across a variety of diseases including 97% of eyes with AMD have peripheral changes²³
 - **opto**map *blue af* is obtained in a single capture in a wavelength consistent with clinical trial imaging standards
- optomap fa may be an effective prognostic marker to better predict risk of worsening over time²⁴
 - Higher risk of progression has been associated with areas of nonperfusion greater than 77.5mm² ²⁵ or 107.3 disc areas²⁶
- optomap icg visualized peripheral changes in 67% ²⁷
- optomap-guided OCT impacts clinical decision making in 84%28
- optomap implementation reduces patient visit duration 33% (28 minutes)²⁹ allowing 4.4% more patients a year (1.5/ day)3
- 97% of optomap users reported unexpected pathology in a patient with no visual complaints³⁰
- OptosAdvance tools allow for the easy assessment of the progression of lesions using image overlay annotations including: area, diameter and change over time



· Optos devices serve as a work horse device for the busy eye care practice providing multi-wavelength retinal imaging for diagnosis and documentation, streamlining capture and review improving clinic flow and efficiency

Neterior 2023 *in press 2. Choudhry, 2019 3. Tornambe, 2017 4. Kernt, 2011 5. Kernt, 2012 6. Silva, 2012 7. Silva, 2013 8. Rasmussen, 2015 9. Silva, 2017 10. Aiello, 2018 11. Cstuak, 2010 12. Ramkumar, 2019 13. Campbell, 2012 14. Drouglazet, 2019 15. Gordon-Shaag, 2014 16. Nagiel, 2016 17. Kumar, 2021 18. OT, 2023 19. Haleel, 2016 20. Chen, 2011. 21. Silva, 2014 22. Sadda, 2012. 23. Friberg, 2016 24. Silva, 2022 25. Nicholson, 2019 26. Yu, 2020 27. Klufas, 2014 28. Sodhi, 2021 29. Lin, 2021 30. Dhoot D, Kitchens JW, Lahners W, Martinez C. Advances in Imaging Online Symposium, Pentavision, 2021

* Feature may not be available in all regions, please check with your representative



Optos UK/Europe +44 (0)1383 843350 ics@optos.com

Optos North America 800 854 3039 usinfo@optos.com

Optos DACH

DE: 0800 72 36 805 AT: 0800 24 48 86 CH: 0800 55 87 39 ics@optos.com

Optos Australia +618 8444 6500

auinfo@optos.com



